StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.00 (+2.24%)

Close on Nov 20, 2026Market cap $9.89MP/E –Yield –

TScan Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

TScan Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$118.44M. For fiscal 2025 it was -$139.73M. The highest annual figure on record is -$7.26M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$139.73M–
FY2024Dec 31, 2024-$114.65M–
FY2023Dec 31, 2023-$64.50M–
FY2022Dec 31, 2022-$70.73M–
FY2021Dec 31, 2021-$58.62M–
FY2020Dec 31, 2020-$7.26M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$28.03M–
Q1 FY2026Mar 31, 2026-$24.35M–
Q4 FY2025Dec 31, 2025-$32.17M–
Q3 FY2025Sep 30, 2025-$33.89M–
Q2 FY2025Jun 30, 2025-$34.55M–
Q1 FY2025Mar 31, 2025-$39.12M–
Q4 FY2024Dec 31, 2024-$28.30M–
Q3 FY2024Sep 30, 2024-$29.29M-543.9%
Q2 FY2024Jun 30, 2024-$27.09M–
Q1 FY2024Mar 31, 2024-$29.97M–
Q4 FY2023Dec 31, 2023-$24.24M–
Q3 FY2023Sep 30, 2023$6.60M–
Q2 FY2023Jun 30, 2023-$22.44M–
Q1 FY2023Mar 31, 2023-$24.43M–
Q4 FY2022Dec 31, 2022-$17.39M–
Q3 FY2022Sep 30, 2022-$17.43M–
Q2 FY2022Jun 30, 2022-$15.26M–
Q1 FY2022Mar 31, 2022-$20.66M–
Q4 FY2021Dec 31, 2021-$16.59M–
Q3 FY2021Sep 30, 2021-$14.49M–
Q2 FY2021Jun 30, 2021-$14.62M–
Q1 FY2021Mar 31, 2021-$12.92M–
Q4 FY2020Dec 31, 2020-$8.74M–
Q3 FY2020Sep 30, 2020-$7.13M–

More TScan Therapeutics figures

See a number that looks wrong?